Description
Dapotron 30 (Dapoxetine 30mg)
Dapotron 30 (Dapoxetine 30mg) is a medicinal product aimed at treating premature ejaculation in adult men. As an effective selective serotonin reuptake inhibitor (SSRI), this tablet enhances the time it takes to ejaculate and provides better control over ejaculation, thus helping to alleviate frustration or anxiety associated with rapid ejaculation. It is typically taken 1 to 3 hours before anticipated sexual activity. Follow the prescribed guidelines and not exceed one tablet per day to ensure safety and efficacy.
Uses Of Dapotron 30 (Dapoxetine 30mg)
- Treatment of premature ejaculation
Treatment of premature ejaculation by increasing serotonin levels in the brain, resulting in delayed ejaculation and improved control over ejaculation. This, in turn, helps alleviate any associated worries or frustrations.
Safety & Precautions
- Do not consume alcohol while taking this medication.
- Avoid using if you have heart-related problems.
- Consult your doctor if you have a history of depression or mania.
- Inform your doctor if you are taking MAO inhibitors.
- Discuss your epilepsy condition with your doctor before taking this medicine.
- Let your doctor know about any liver or kidney diseases you have.
- Discuss glaucoma or history of dizziness/fainting with your doctor.
- Pregnant or breastfeeding women should consult their doctor before use.
- Do not take more than one tablet in a day.
- Avoid driving or operating heavy machinery until you know how this medicine affects you.
Side Effects
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them.
- Drowsiness
- Nausea
- Tremors
- Vomiting
- Dizziness
- Erectile dysfunction
- Fatigue
- Headache
- Increased sweating
- Indigestion
- Restlessness
- Insomnia (difficulty in sleeping)
- Eye pain
- Agitation
FAQ
1. What is Dapotron 30 (Dapoxetine 30mg) used for?
Dapotron 30 (Dapoxetine 30mg) is primarily used for the treatment of premature ejaculation in adult men. The medicine increases the level of serotonin in the brain, helping to delay ejaculation and improve control over it, thus reducing any anxiety or frustration related to rapid ejaculation.
2. How should I take Dapotron 30 (Dapoxetine 30mg)?
You should take Dapotron 30 (Dapoxetine 30mg) exactly as prescribed by your doctor. The medication is typically taken 1 to 3 hours before anticipated sexual activity. It may be taken with or without food. Do not exceed more than one tablet per day to ensure safety.
3. Can I drink alcohol while taking Dapotron 30 (Dapoxetine 30mg)?
It is unsafe to consume alcohol while taking Dapotron 30 (Dapoxetine 30mg). Alcohol can increase the likelihood of experiencing side effects like dizziness, fatigue, and drowsiness, which could impair your ability to perform activities that require focus.
4. Are there any potential side effects of Dapotron 30 (Dapoxetine 30mg)?
Yes, there are potential side effects associated with Dapotron 30 (Dapoxetine 30mg). Common side effects include drowsiness, nausea, tremors, vomiting, dizziness, erectile dysfunction, fatigue, headache, increased sweating, indigestion, restlessness, insomnia, eye pain, and agitation. Most of these side effects do not require medical attention and typically subside as the body adjusts to the medication. Consult your doctor if you experience any persistent or worrisome side effects.
5. Who should not take Dapotron 30 (Dapoxetine 30mg)?
Individuals with heart problems such as heart failure or irregular heart rhythms, a history of depression or mania, or those currently taking MAO inhibitors for depression should not take Dapotron 30 (Dapoxetine 30mg). Additionally, patients with epilepsy, liver or kidney disease, glaucoma, or a history of dizziness or fainting due to low blood pressure should consult their doctor before taking this medication.
6. Can Dapotron 30 (Dapoxetine 30mg) be taken by women?
No, Dapotron 30 (Dapoxetine 30mg) is not indicated for use in women. It is specifically formulated to treat premature ejaculation in adult men. If women have any concerns related to premature ejaculation or other health issues, they should consult their healthcare provider for appropriate treatments and recommendations.
Additional Information
Pharmacokinetics and Metabolism of Dapotron 30 Dapoxetine (30mg)
Dapoxetine undergoes rapid absorption and elimination, leading to minimal accumulation within the body. It demonstrates dose-proportional pharmacokinetics, which remain unaffected by multiple dosing and do not vary significantly between different ethnic groups. This metabolic profile suggests that Dapoxetine is a viable candidate for on-demand treatment of premature ejaculation (PE).
| Pharmacokinetic Parameter | Dapoxetine 30 mg | Dapoxetine 60 mg |
|---|---|---|
| Cmax (ng/ml) | 297 | 498 |
| Tmax (h) | 1.01 | 1.27 |
| Initial Half-Life (h) | 1.31 | 1.42 |
| Terminal Half-Life (h) | 18.7 | 21.9 |
Food does not significantly impact the pharmacokinetics of Dapoxetine. Although a high-fat meal slightly reduces the plasma concentration (Cmax) and delays Tmax by approximately 0.5 hours, the overall absorption and elimination characteristics of Dapoxetine remain largely unaffected.
Clinical Efficacy of Dapotron 30 Dapoxetine (30mg)
The efficacy of Dapotron 30 Dapoxetine (30mg) has been demonstrated through various phase II and phase III trials. The results indicate significant improvements in intravaginal ejaculatory latency time (IELT) and patient-reported outcomes (PROs).
Phase II Trials
Two multicenter phase II trials established the dose-ranging efficacy of Dapotron 30 Dapoxetine (30mg). Both utilized a randomized, placebo-controlled, double-blind, three-period, crossover design, including men diagnosed with PE using DSM-IV criteria and a baseline IELT of less than 2 minutes.
- Subjects were required to attempt intercourse at least twice a week, and the primary outcome measure was the partner-operated stopwatch IELT.
- All four doses tested (20 mg, 40 mg, 60 mg, 100 mg) were effective and significantly superior to placebo, increasing IELT 2.0–3.2 fold over the baseline in a dose-dependent manner.
| Dapoxetine Dose | Study 1 IELT (minutes) | Study 2 IELT (minutes) |
|---|---|---|
| 20 mg | 2.72* | – |
| 40 mg | 3.31† | – |
| 60 mg | – | 2.86† |
| 100 mg | – | 3.24† |
| Placebo | 2.22 | 2.07 |
Phase III Trials
Five randomized, placebo-controlled phase III trials confirmed the efficacy and safety of Dapotron 30 Dapoxetine (30mg). Collectively, these studies involved over 6,000 men from 32 countries, demonstrating the substantial efficacy of Dapoxetine across different demographics.
- Subjects reported having PE for an average of 15.1 years, and 64.9% were classified as having lifelong PE.
- Outcome measures included stopwatch IELT, the Premature Ejaculation Profile (PEP), and the Clinical Global Impression of Change (CGIC) in PE.
| Parameter | Baseline IELT (minutes) | 12-Week Treatment IELT (minutes) | P-Value |
|---|---|---|---|
| Placebo | 0.9 | 1.9 | – |
| Dapoxetine 30 mg | 0.9 | 3.1 | <0.001 |
| Dapoxetine 60 mg | 0.9 | 3.6 | <0.001 |
Patient-Reported Outcomes
Overall, patients reported significant improvements in perceived control over ejaculation, satisfaction with sexual intercourse, and reductions in ejaculation-related personal and interpersonal distress.
- Control over ejaculation was reported as ‘good’ or ‘very good’ by less than 1% of men at baseline, increasing to 26.2% with Dapoxetine 30 mg and 30.2% with Dapoxetine 60 mg after 12 weeks.
- Satisfaction with sexual intercourse improved substantially, with ‘good’ or ‘very good’ satisfaction reported by 37.9% and 42.8% of men administered Dapoxetine 30 mg and 60 mg, respectively.
- Ejaculation-related personal distress reduced from approximately 70% at baseline to 28.2% and 22.2% with Dapoxetine 30 mg and 60 mg, respectively.
- Interpersonal difficulty related to ejaculation also decreased significantly, with similar trends observed in partner-reported outcomes, including satisfaction and perceived control over ejaculation.
Animal Studies
Animal models have demonstrated that acute treatment with Dapoxetine at doses as low as 1 mg/kg effectively inhibits ejaculation. These findings support the clinical observations that Dapoxetine acts on the ejaculatory reflex at a supraspinal level, particularly involving brain areas such as the lateral paragigantocellular nucleus.
Management of Premature Ejaculation with Dapotron 30 Dapoxetine (30mg)
Treatment of premature ejaculation (PE) often involves a multifaceted approach, including pharmacotherapy, psychotherapy, or both. The Dapotron 30 Dapoxetine (30mg) stands as a distinct option due to its on-demand dosing regimen, offering convenience and effective control over ejaculation for many men.
- Dapoxetine can be used for both lifelong and acquired PE. The recommended initial dose is 30 mg, taken 1–3 hours before sexual activity.
- If the effect of 30 mg is insufficient and side effects are manageable, the dose may be increased to a maximum of 60 mg.
- Unlike chronic SSRI administration, on-demand dosing minimizes the risk of serotonin receptor desensitization and downregulation, which reduces the likelihood of withdrawal symptoms.
- In men with acquired PE and comorbid erectile dysfunction (ED), Dapoxetine can be co-prescribed with phosphodiesterase type-5 (PDE-5) inhibitors such as sildenafil or tadalafil without significant pharmacokinetic interactions.
Conclusion
The Dapotron 30 Dapoxetine (30mg) provides a significantly effective and safe on-demand treatment for PE, addressing a substantial unmet need in sexual medicine. The comprehensive clinical trials supporting its efficacy and safety underscore Dapoxetine’s role in transforming PE management. As the only SSRI specifically developed for PE, Dapoxetine offers a unique treatment option, providing therapeutic benefits with a favorable safety profile.
Cited Sources:
- McMahon, C.G., et al. “Dapoxetine: a new option in the medical management of premature ejaculation.” Ther Adv Urol. 2012; 4: 233–251.
- Waldinger, M.D., et al. “Proposal for a definition of lifelong premature ejaculation based on epidemiological stopwatch data.” J Sex Med. 2005; 2: 498–507.
- Giuliano, F., et al. “Premature ejaculation: results from a five-country European observational study.” Eur Urol. 2008; 53: 1048–1057.
